These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks. Desai MY; Owens A; Geske JB; Wolski K; Saberi S; Wang A; Sherrid M; Cremer PC; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Balasubramanyam A; Lampl K; Sehnert AJ; Nissen SE Circulation; 2023 Mar; 147(11):850-863. PubMed ID: 36335531 [TBL] [Abstract][Full Text] [Related]
11. Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. Wheeler MT; Jacoby D; Elliott PM; Saberi S; Hegde SM; Lakdawala NK; Myers J; Sehnert AJ; Edelberg JM; Li W; Olivotto I Eur J Heart Fail; 2023 Feb; 25(2):260-270. PubMed ID: 36404399 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Ammirati E; Contri R; Coppini R; Cecchi F; Frigerio M; Olivotto I Eur J Heart Fail; 2016 Sep; 18(9):1106-18. PubMed ID: 27109894 [TBL] [Abstract][Full Text] [Related]
13. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy. Yacoub MS; El-Nakhal T; Hasabo EA; Shehata N; Wilson K; Ismail KH; Bakr MS; Mohsen M; Mohamed A; Abdelazim E; Ali HT; Soliman Z; Sayed A; Abdelsayed K; Caliskan K; Soliman O Heart Fail Rev; 2024 Mar; 29(2):479-496. PubMed ID: 38112937 [TBL] [Abstract][Full Text] [Related]
14. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit. Desai N; Xie J; Wang Y; Sutton MB; Whang J; Fine JT; Garrison LP Clin Ther; 2022 Jan; 44(1):52-66.e2. PubMed ID: 34911641 [TBL] [Abstract][Full Text] [Related]
15. [Hypertrophic cardiomyopathy (HCM). Surgical versus drug therapy]. Schulte HD; Gramsch-Zabel H; Schwartzkopff B; Gams E Z Kardiol; 1999 Mar; 88(3):163-72. PubMed ID: 10355066 [TBL] [Abstract][Full Text] [Related]
16. Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy. Packard E; de Feria A; Peshin S; Reza N; Owens AT Cardiol Ther; 2022 Dec; 11(4):491-507. PubMed ID: 36243823 [TBL] [Abstract][Full Text] [Related]
17. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy. Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706 [TBL] [Abstract][Full Text] [Related]
18. Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management. Sykuta A; Yoon CH; Baldwin S; Rine NI; Young M; Smith A Ann Pharmacother; 2024 Mar; 58(3):273-285. PubMed ID: 37329113 [TBL] [Abstract][Full Text] [Related]
19. Obstructive hypertrophic cardiomyopathy: a review of new therapies. Mehra N; Ali AH; Desai MY Future Cardiol; 2023 Oct; 19(13):661-670. PubMed ID: 37933625 [TBL] [Abstract][Full Text] [Related]
20. Impact of peak provoked left ventricular outflow tract gradients on clinical outcomes in hypertrophic cardiomyopathy. Lu DY; Hailesealassie B; Ventoulis I; Liu H; Liang HY; Nowbar A; Pozios I; Canepa M; Cresswell K; Luo HC; Abraham MR; Abraham TP Int J Cardiol; 2017 Sep; 243():290-295. PubMed ID: 28747034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]